High Water versus Ad libitum Water Intake for Autosomal Dominant Polycystic Kidney Disease: A Randomised Controlled Feasibility Trial.
Vasopressin stimulates cyst growth in Autosomal Dominant Polycystic Kidney Disease (ADPKD) and is a key therapeutic target. Evaluation of High Water intake as an alternative to pharmacological vasopressin blockade is supported by patients. However feasibility, safety and adherence-promoting strategies required to deliver this remain unknown. Assess the feasibility of a definitive randomised high water intake trial in ADPKD. In this prospective open-label randomised trial, adult ADPKD patients with eGFR≥20ml/min/1.73m2 were randomised to prescribed high water intake (HW) targeting urine osmolality (UOsm) ≤270mOsm/kg, or ad libitum (AW) intake (UOsm >300mOsm/Kg). Self-management strategies including home-monitoring of urine specific gravity (USG) were employed to promote adherence. We enrolled 42 participants, baseline median eGFR (HW 68.4 [IQR 35.9-107.2] vs AW 75.8 [IQR 59.0-111.0 mls/min/1.73m2, P = 0.22) and UOsm (HW 353 [IQR 190-438] vs AW 350 [IQR 240-452] mOsm/kg, P = 0.71) were similar between groups. After 8 weeks, 67% in the HW versus 24% in AW group achieved UOsm ≤270mOsm/kg, p = 0.001. HW group achieved lower UOsm (194 [IQR 190-438] v 379 [IQR 235-503] mOsm/kg, p = 0.01) and higher urine volumes (3155 [IQR2270-4295] vs 1920 [IQR1670-2960] mls/day, p = 0.02). Two cases of hyponatraemia occurred in HW group. No acute GFR effects were detected. 79%(519/672) of USG were submitted and 90%(468/519) were within target. Overall, 17% withdrew during the study. DRINK demonstrated successful recruitment and adherence leading to separation between treatment arms in primary outcomes. These findings suggest a definitive trial assessing the impact of high water on kidney disease progression in ADPKD is feasible.